An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants withEpidermal Growth Factor Receptor Mutation-Positive Stage II-IIIB Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (TARGET)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508740-21-00

Acronym

D5162C00048

Enrollment

125

Registered

2024-02-26

Start date

2023-02-15

Completion date

Unknown

Last updated

2025-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Brief summary

DFS at 5 years per the investigator's assessment in the Common EGFRm Cohort

Detailed description

The measure of interest is the proportion of participants alive and disease-free at 3, 4, and 5 years, The measure of interest is the proportion of participants alive and disease-free at 3 and 4 years, The measure of interest is the proportion of participants alive at 3, 4, and 5 years

Interventions

DRUGTAGRISSO 80 mg film-coated tablets

DRUGTAGRISSO 40 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
DFS at 5 years per the investigator's assessment in the Common EGFRm Cohort	—

Secondary

Measure	Time frame
The measure of interest is the proportion of participants alive and disease-free at 3, 4, and 5 years, The measure of interest is the proportion of participants alive and disease-free at 3 and 4 years, The measure of interest is the proportion of participants alive at 3, 4, and 5 years	—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026